Skip to Content

Fotivda (tivozanib) and Alcohol / Food Interactions

There are 2 alcohol/food/lifestyle interactions with Fotivda (tivozanib) which include:

Moderate

High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

naxitamab-gqgk - hypertension

Hypertension has been observed in patients treated with naxitamab. Most hypertensive events occurred on the day of the infusion and may occur up to 9 days after the infusion. Do not administer this drug to patients with uncontrolled hypertension. Interrupt therapy and resume at a reduced rate or permanently discontinue based on severity. It is recommended to monitor blood pressure during the infusion, an at least daily on Days 1 to 8 of each cycle.

Moderate

High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

tivozanib - hypertension

Tivozanib has not been studied in patients with systolic blood pressure greater than 150 mmHg or diastolic blood pressure greater than 100 mmHg. Control blood pressure prior to initiating therapy. Monitor blood pressure after 2 weeks and at least monthly thereafter. Treat patients with antihypertensives when hypertension occurs. Withhold therapy for severe hypertension despite optimal antihypertensive therapy. For persistent hypertension (despite use of antihypertensive medications), reduce the dose. Discontinue if hypertension is severe and persistent despite antihypertensive therapy and dose reduction or in patients who experience hypertensive crisis.

Fotivda (tivozanib) drug interactions

There are 41 drug interactions with Fotivda (tivozanib)

Fotivda (tivozanib) disease interactions

There are 9 disease interactions with Fotivda (tivozanib) which include:

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.